Introduction
aggressive clinical behavior, TNBC, breast cancer
TRIPLE-NEGATIVE BREAST CANCER, BREAST CANCERS, BREAST CANCER
Defined by the absence of expression of endocrine receptors and lack of human epidermal growth factor receptor 2 (HER2) gene amplification, triple-negative breast cancer (TNBC) represents 15% to 20% of all breast cancers. TNBC has the worst outcome of all breast cancer subtypes, aggressive clinical behavior, a high rate of early relapses, and limited treatment optionsFurthermore, a subset of patients treated with ICI in the early setting (~16% at 3 years) will relapse, and new treatment strategies are neededThe randomized phase I/II SYNERGY trial (NCT03616886) evaluated the safety and efficacy of adding oleclumab to the combination of durvalumab with chemotherapy in patients with untreated locally-advanced or mTNBC